How Will the Market React to Adagene Inc (ADAG) Stock Getting a Bullish Rating

Overall market sentiment has been high on Adagene Inc (ADAG) stock lately. ADAG receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Adagene Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ADAG!

See Full ADAG Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ADAG Stock Today?

Adagene Inc (ADAG) stock has fallen -2.83% while the S&P 500 has gained 0.1% as of 2:26 PM on Wednesday, May 3. ADAG has fallen -$0.04 from the previous closing price of $1.33 on volume of 24,407 shares. Over the past year the S&P 500 is down -0.76% while ADAG has fallen -64.46%. ADAG lost -$1.85 per share in the over the last 12 months. To screen for more stocks like Adagene Inc click here.

More About Adagene Inc

Adagene Inc. Nasdaq: ADAG is a biotechnology company transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary DPL platform composed of NEObody SAFEbody and POWERbody technologies Adagenes highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science. Click Here to get the full Stock Report for Adagene Inc stock.